COVID-19 Impacts: Cell Viability Assays Market will Accelerate at a CAGR of over 8% through 2020-2024 | Focus on Timely Diagnosis of Diseases to Boost…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cell viability assays market and it is poised to grow by USD 1.40 billion during 2020-2024, progressing at a CAGR of over 8% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request the Latest Free Sample Report on COVID-19 Impact

Frequently Asked Questions-

The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Agilent Technologies Inc., Becton, Dickinson and Co., Bio-Rad Laboratories Inc., Biotium Inc., Danaher Corp., General Electric Co., Merck KGaA, PerkinElmer Inc., Promega Corp., and Thermo Fisher Scientific Inc. are some of the major market participants. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

Focus on the timely diagnosis of diseases has been instrumental in driving the growth of the market. However, limitations associated with cell viability assays might hamper market growth.

Cell Viability Assays Market 2020-2024: Segmentation

Cell Viability Assays Market is segmented as below:

To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR40302

Cell Viability Assays Market 2020-2024: Scope

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our cell viability assays market report covers the following areas:

This study identifies the growing focus on stem cell research as one of the prime reasons driving the cell viability assays market growth during the next few years.

Cell Viability Assays Market 2020-2024: Vendor Analysis

We provide a detailed analysis of around 25 vendors operating in the cell viability assays market, including some of the vendors such as Agilent Technologies Inc., Becton, Dickinson and Co., Bio-Rad Laboratories Inc., Biotium Inc., Danaher Corp., General Electric Co., Merck KGaA, PerkinElmer Inc., Promega Corp., and Thermo Fisher Scientific Inc. Backed with competitive intelligence and benchmarking, our research reports on the Cell Viability Assays Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Cell Viability Assays Market 2020-2024: Key Highlights

Table of Contents:

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

PART 04: MARKET SIZING

PART 05: FIVE FORCES ANALYSIS

PART 06: MARKET SEGMENTATION BY PRODUCT

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

PART 14: APPENDIX

PART 15: EXPLORE TECHNAVIO

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Originally posted here:
COVID-19 Impacts: Cell Viability Assays Market will Accelerate at a CAGR of over 8% through 2020-2024 | Focus on Timely Diagnosis of Diseases to Boost...

Stem Cell Manufacturing Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic and Non-Economic Aspects By 2027…

New Jersey, United States,- The recent report on Stem Cell Manufacturing Market offered by Verified Market Research, comprises of a comprehensive investigation into the geographical landscape, industry size along with the revenue estimation of the business. Additionally, the report also highlights the challenges impeding market growth and expansion strategies employed by leading companies in the Stem Cell Manufacturing market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

In market segmentation by manufacturers, the report covers the following companies-

Exploring the growth rate over a period

Business owners looking to scale up their business can refer this report that contains data regarding the rise in sales within a given consumer base for the forecast period, 2020 to 2027. Product owners can use this information along with the driving factors such as demographics and revenue generated from other products discussed in the report to get a better analysis of their products and services. Besides, the research analysts have compared the market growth rate with product sales to enable business owners to determine the success or failure of a specific product or service.

By Type

Type 1

Type 2

By Application

Application1

Application 2

Global Stem Cell Manufacturing Market Report 2020 Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Stem Cell Manufacturing industry.

The report at a glance

The Stem Cell Manufacturing market report focuses on economic developments and consumer spending trends across different countries for the forecast period 2019 to 2026. The research further reveals which countries and regions will have a better standing in the years to come. Apart from this, the study talks about the growth rate, market share as well as the recent developments in the Stem Cell Manufacturing industry worldwide. Besides, the special mention of major market players adds importance to the overall market study.

Market segment by Region/Country including:

North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia and Spain etc.) Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) South America (Brazil, Argentina, Colombia and Chile etc.) Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

The research provides answers to the following key questions:

What is the expected growth rate of the Stem Cell Manufacturing market? What will be the market size for the forecast period, 20202027?

What are the major driving forces responsible for transforming the trajectory of the industry?

Who are major vendors dominating the Stem Cell Manufacturing industry across different regions? What are their winning strategies to stay ahead in the competition?

What are the market trends business owners can rely upon in the coming years?

What are the threats and challenges expected to restrict the progress of the industry across different countries?

What are the key opportunities that business owners can bank on for the forecast period, 20202027?

Why Choose Verified Market Research?

To summarize, the global Stem Cell Manufacturing market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080 UK: +44 (203)-411-9686 APAC: +91 (902)-863-5784 US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

See more here:
Stem Cell Manufacturing Market Segmentation By Qualitative And Quantitative Research Incorporating Impact Of Economic and Non-Economic Aspects By 2027...

Stem Cell Banking Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By DataIntelo – Owned

The Global Stem Cell Banking Market analysis report published on Dataintelo.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://dataintelo.com/request-sample/?reportId=109977

The Global Stem Cell Banking Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Stem Cell Banking Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Stem Cell Banking Market Report: https://dataintelo.com/enquiry-before-buying/?reportId=109977

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Stem Cell Banking Market as: Global Stem Cell Banking Market Size & Share, by Regions

Global Stem Cell Banking Market Size & Share, by Products Umbilical Cord Blood Stem Cell Embryonic Stem Cell Adult Stem Cell Other

Global Stem Cell Banking Market Size & Share, Applications Diseases Therapy Healthcare

Key Players CCBC CBR ViaCord Esperite Vcanbio Boyalife LifeCell Crioestaminal RMS Regrow Cordlife Group PBKM FamiCord cells4life Beikebiotech StemCyte Cryo-cell Cellsafe Biotech Group PacifiCord Americord Krio Familycord Cryo Stemcell Stemade Biotech

Avail the Discount on this Report @ https://dataintelo.com/ask-for-discount/?reportId=109977

Dataintelo offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex Mathews Address: 500 East E Street, Ontario, CA 91764, United States. Phone No: USA: +1 909 545 6473 | IND: +91-7000061386 Email: [emailprotected] Website: https://dataintelo.com

See the original post:
Stem Cell Banking Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By DataIntelo - Owned

R3 International Offering New Stem Cell Therapy for Neuropathy Program in Mexico – Benzinga

SCOTTSDALE, Ariz., July 23, 2020 /PRNewswire-PRWeb/ -- R3 International is now offering a new stem cell therapy for neuropathy program in Mexico. The regenerative treatments involve up to 200 million stem cells and have been very effective at relieving neuropathic pain.

Peripheral neuropathy affects many millions of Individuals worldwide, and often leads to chronic, debilitating pain. It may occur as a result of diabetes, alcoholism, radiation, chemo or many other potential causes.

Stem cell and exosome therapy for neuropathy has achieved tremendous results at R3 International. Stem cells and exosomes are excellent at promoting nerve regeneration and new blood vessel formation.

According to R3 CEO David Greene, MD, MBA, "Patients lament the traditional pain medications they are offered for relief, which may lead to addiction or an overdose. The stem cell and exosome therapy offered at R3 International is safe and very effective for relief and helping patients be able to walk farther."

Treatments at the clinic are outpatient, and involve anywhere from 30 million stem cells up to 200 million. The treatment starts at only $2975, with escorted transportation included from San Diego to the clinic and back. The patient concierge representative goes with the patient to the treatment as well.

The process starts with a free phone consultation with the R3 licensed, experienced stem cell doctor. Once treatment is scheduled, the R3 patient concierge assists with travel logistics.

In addition to the neuropathy stem cell program, R3 International also provides stem cell treatment in Mexico for COPD, kidney failure, autism, arthritis, diabetes, hepatitis, Lyme disease, MS, ALS, Alzheimers and more.

Call (888) 988-0515 to schedule the free phone consultation.

SOURCE R3 Stem Cell International

Read the original:
R3 International Offering New Stem Cell Therapy for Neuropathy Program in Mexico - Benzinga

Two people receive helping hand from Centre to get their advanced treatment in Delhi amid COVID-19 lockdown – Yahoo India News

New Delhi [India], July 25 (ANI): As India faced a complete lockdown till May due to the COVID-19 pandemic, the government lent a helping hand to two people -- one Indian and a Nepali national from Australia -- to get their advanced treatment in Delhi.

Fifteen-year-old Nitya Singh (name changed) from Punjab, who was diagnosed with very severe aplastic anemia, was granted special permission to reach a Delhi hospital for advanced treatment.

Similarly, Arjun Prasad Timilsina, a 31-year-old Nepali national, was airlifted from Australia by an Air India flight (AI-301) to Delhi to get the bone marrow transplant which is a lifesaving treatment.

According to Nitya's doctors, her condition started to deteriorate due to her medical condition and suggested a bone marrow transplant for her.

On the other hand, Timilsina was living in Australia. He was diagnosed with acute myeloid leukaemia early this year. Timilsina underwent few cycles of chemotherapy in Australia, but the induction therapy failed twice following which he was given a high dose of chemotherapy.

Timilsina's family connected with doctors at the BLK Super Speciality Hospital in Delhi through e-mails and video conferencing. After going through his reports, medical experts suggested him a bone marrow transplant as the only treatment. In May, Timilsina decided to come to India for the treatment.

Dr Dharma Choudhary, Senior Director and HoD, Centre for Hemato-oncology and bone marrow transplant, BLK Super Speciality Hospital, and his team performed the bone marrow transplant on both the patients during the lockdown.

"Her (Nitya) parents took special permission from the state government authorities as the lockdown was prevailing in the entire country due to the ongoing coronavirus pandemic. In the utmost emergency, we decided to take Nitya's mother as a donor. All the requisite tests were done and her mother was fit to be a donor for the half match allogeneic bone marrow transplant. The procedure performed on June 2," Dr Choudhary told ANI.

Nitya accepted the graft well and got discharged in the third week of June. Presently, the patient is well and is doing a regular follow-up with us, he said.

Dr Choudhary said that Timilsina contacted the Indian and Nepali embassies in Australia and the Union Health Ministry.

"His efforts worked and finally he was airlifted from Australia to India through Vande Bharat Mission flight along with his brother who was a complete match for the bone marrow transplant. After thorough investigations, he underwent successful allogeneic stem cell transplant from full match sibling donor (brother) on June 11. We kept him under close observation for several days and currently he is in good condition. He has been discharged," he added.

"Delay in these treatments could result in severe consequences. But thanks to the Punjab government, Ministry of Health, Indian and Nepali embassies who helped these patients reach the hospital on time to get the required treatment," Dr Choudhary further said. (ANI)

Original post:
Two people receive helping hand from Centre to get their advanced treatment in Delhi amid COVID-19 lockdown - Yahoo India News

Trending News on Targeted Oncology, Week of July 24, 2020 – Targeted Oncology

In oncology news this week, the FDA accepted a supplemental New Drug Application for selinexor(Xpovio) as treatment of patients with relapsed or refractory multiple myeloma who had received at least 1 prior line of therapy. Meanwhile, theFDA granted clearance for the cancer drug abivertinib to be investigated in a phase 2 study as treatment of hospitalized patients with coronavirus disease 2019 (COVID-19).

This week Targeted Oncology hosted a tweet chat with Alexander N. Shoushtari, MD, of Memorial Sloan Kettering Cancer Center, to discussion the case of a 52-year-old woman withBRAF-mutant metastatic melanoma. Following the tweet chat, Shoushtari continued the discussion in an interview.

Sorafenib Maintenance May Prevent Recurrence After Transplant in FLT3-ITD+ AML

The risk of relapse or death was reduced by 61% with the use of sorafenib maintenance therapy compared with placebo following allogeneic hematopoietic stem cell transplantation in patients withFLT3-ITDpositive acute myeloid leukemia, according to the results of the phase 2 SORMAIN trial.

Ruxolitinib Reduces Spleen Size in Patients With Myelofibrosis and Low-Platelet Counts

Ruxolitinib, the JAK1/2 inhibitor, induced significant spleen responses in patients with myelofibrosis, both with general disease and in patients with low platelet counts, according to results from the phase 3b JUMP study.

Pivotal Phase 3 Trial Initiated to Study Promising Cabozantinib/Atezolizumab Combo in Advanced RCC

A pivotal phase 3 trial has been initiated to explore the combination of cabozantinib and atezolizumab for the treatment of patients with inoperable, locally advanced or metastatic renal cell carcinoma who progressed during or after treatment with an immune checkpoint inhibitor immediately following initial therapy.

CLR 131 Induces Encouraging Responses in Relapsed/Refractory LPL and WM

CLR 131 induced an objective response rate of 100% as treatment of patients with relapsed/refractory lymphoplasmacytic lymphoma and Waldenstrms macroglobulinemia in the ongoing phase 2 CLOVER-1 study.

Avelumab Plus TG4001 Shows Promising Efficacy in HPV16-Positive Metastatic Cancers

Avelumab in combination with a novel HPV16-targeted vaccine, demonstrated clinical activity as treatment of patients with HPV16-positive recurrent and/or metastatic malignancies, a phase 1b/2 clinical trial showed.

A 79-Year-Old Man With Relapsed Chronic Lymphocytic Leukemia

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia in this episode of Targeted Oncology Case Based Peer Perspectives series.

Analyzing the Importance of Biomarker Testing and MSI Status in mCRC

Heinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate 142 trial.

Limited Toxicity Seen With Leronlimab in Mild to Moderate COVID-19

Treatment with leronlimab in patients with mild to moderate symptoms of respiratory illness from COVID-19 caused fewer serious adverse events when compared with placebo, according to safety results from a phase 2 clinical trial.

Study Shows Disparities, Effects of Treatment for Patients With Cancer and COVID-19

Data from a treatment utilization study revealed racial disparities in treatments for COVID-19 as well as the effects and clinical outcomes of treatments such as remdesivir and dexamethasone in patients with cancer who were diagnosed with COVID-19.

View post:
Trending News on Targeted Oncology, Week of July 24, 2020 - Targeted Oncology

US regulations for regenerative medicine advanced therapies – Regulatory Focus

This article examines US regulations and guidance documents for regenerative medicine advanced therapies (RMATs). The author describes the field of regenerative medicine, noting that it is expanding at an accelerated pace, and outlines some of the common terms associated with it. He also addresses the application process for these therapies, accelerated regulatory pathways, market access, and the outlook for RMATs. The author cautions that, as exciting as these therapies are, they require a rigorous and carefully planned approach to ensure a seamless progression to regulatory approval and commercial success. Introduction Regenerative medicine is a rapidly expanding field, offering the potential to treat serious and life-threatening conditions by replacing, or regenerating, human cells, tissues, or organs that have been damaged by disease, trauma, or congenital defects.1 With more than 200 investigational new drug (IND) applications anticipated by the US Food and Drug Administration (FDA) in 2020,2 regenerative medicine should yield many new therapies with enormous benefits to patients, especially those with unmet medical needs. Navigating the complex regulatory environment of regenerative medicine requires companies to engage with the FDA early and often throughout the drug development process to identify and overcome potential obstacles to approval. Many of these therapies are developed by scientific institutions and medical research groups with limited inhouse regulatory resources, so it is advisable to seek external regulatory support early in the planning process. Regenerative medicines defined Regenerative medicines, as defined by the FDA, include cell therapies (non- and genetically modified), therapeutic tissue-engineering products, human cell and tissue products, and combination products using these biologic components, which lead to a sustained effect on cells and tissues. In addition, a combination product (biologic device, biologic drug, or biologic device-drug) can be eligible for regenerative medicine advanced therapy (RMAT) designation when the biological product constituent part is a regenerative medicine therapy and provides the greatest contribution to the overall intended therapeutic effects of the combination product (i.e., the primary mode of action of the combination product is conveyed by the biological product constituent part). In January 2020, the FDA released six final guidances on gene therapy manufacturing and clinical development of products and a draft guidance.3 The FDAs policy to advance the development of safe and effective cell and gene therapies can be found here.4 This article explains some of the terminology and covers the key US regulations and guidance documents. Discussions of a select number of these documents will be published in separate articles in Regulatory Focus. Terminology Cellular & gene therapy products5 Cellular therapy products include cellular immunotherapies, cancer vaccines, and other types of autologous and allogeneic cells, including hematopoietic stem cells and adult and embryonic stem cells, for certain therapeutic indications. Human gene therapy seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use. The FDAs Center for Biologics Evaluation and Research (CBER) has approved both cellular and gene therapy products.5 Gene therapy6 Gene therapy is a technique that modifies a persons faulty genes treat or cure disease and is most often applied to cancer, genetic diseases and infectious diseases. Gene therapies can work by several mechanisms:

The following figureshows CBERs organisation for pre and postmarket regulation35

Market access and outlook As of May 2019, the FDA had granted 34 products FDA regenerative medicine advanced therapy designations.36 In all, 68 of the 100 designation applications were cell therapy products, 20 of the 34 RMAT granted products have orphan product designation, and 11 of the 34 have fast track designation. While the promise of regenerative medicines to cure disease is driving the field forward at an accelerated pace, developing these therapies require a rigorous and carefully planned approach to ensure a seamless progression to regulatory approval and commercial success. Abbreviations ANDA, abbreviated new drug application; CBER, Center for Biologics Evaluation and Research; FDA, Food and Drug Administration; HCT/P, human cell, tissue, and cellular and tissue-based product; IND, investigational new drug; PDUFA, Prescription Drug User Fee Act; rDNA, ribosomal DNA; RMAT, regenerative medicine advanced therapy. References All references were accessed 23 July 2020.

Read the original here:
US regulations for regenerative medicine advanced therapies - Regulatory Focus

This is What He and His Family Are Working Towards- Former Ferrari Head Todt Reveals He Saw Michael Schumacher Last Week – Essentially Sports

Gauging the progress made by Formula 1 legend, Michael Schumacher, as far as his health is concerned, often seems like a losing battle. The Schumacher family has mostly been very private about the 7-time world champions condition and health ever since he suffered a horrific skiing accident, about 6 and a half years ago.

Last month, reports indicated that the F1 legends stem cell surgery was put on hold due to the pandemic. Since then, there has been no update about Schumis health. Until now.

Former Ferrari CEO Jean Todt, who is a rather close acquaintance to Schumacher, gives fans some reason for optimism.

According to Dailymail, the former CEO of Ferrari said, I saw Michael last week. He is fighting. I hope that the world will be able to see him again. This is what he and his family are working towards.

It may not be a lot in terms of an update, but well savor whatever information we can get about the F1 legend. We wish him a speedy recovery and hope to see him soon enough.

Todt obviously shares a very special connection with Schumi. Todt occupied the role of the Team Principal at Scuderia Ferrari, and he was responsible for bringing Michael in to Ferrari in 1996.

Schumacher, at the time, had won back-to-back world titles with Benetton.

The duo of Todt and Schumacher saw the Maranello-based outfit through their most successful years in the sport of Formula 1.

For five consecutive seasons, Schumacher dominated F1 and won back-to-back world titles. His brilliance also led The Prancing Horse to win 5 back-to-back Constructors championship titles as well.

Thereafter, Todt was promoted to the role of CEO of the Ferrari brand for four years (2004-08). Now he is part of the UN Secretary-Generals special envoy for road safety.

As for Michael, he continued at Ferrari for two more seasons, finishing 3rd and 2nd respectively. After that, the German driver retired from F1 for 3 years.

But the love for the sport couldnt keep him out for long, and he was back for a second stint with Mercedes.

However, that move didnt go to plan and Schumi retired for a second time after the 2013 season. This time for good.

See the original post here:
This is What He and His Family Are Working Towards- Former Ferrari Head Todt Reveals He Saw Michael Schumacher Last Week - Essentially Sports

Covid-19 Updates : Exosome Therapeutic Market 2020-2026 Analysis, Insights, Trends, Key Players, Drivers and Forecast | Leading Players evox…

Data Bridge Market Research (DBMR) has published a latest market research report on Global Exosome Therapeutic Market . The global report is prepared in collaboration with the leading industry experts & dedicated research analyst team to provide an enterprise with in-depth market insights & help them to take crucial business decisions. This report covers current market trends, opportunities, challenges & detailed competitive analysis of the industry players in the market.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

The Global Exosome Therapeutic Market analysis report is a detailed study of market size, share and dynamics covered in 350 pages & is an illustrative sample demonstrating market trends. This is a latest research report , covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life worldwide. This has brought along with several changes in market conditions . The rapidly changing market scenario & initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth & profitability. The report also delivers on key players along with strategic standpoint pertaining to price & promotion.

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in the Exosome Therapeutic Market report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Original post:
Covid-19 Updates : Exosome Therapeutic Market 2020-2026 Analysis, Insights, Trends, Key Players, Drivers and Forecast | Leading Players evox...

First Edition: July 24, 2020 – Kaiser Health News

Today's early morning highlights from the major news organizations.

Kaiser Health News and USA Today: Less-Lethal Weapons Blind, Maim And Kill. Victims Say Enough Is Enough. Theres a gap in Scott Olsens memory for the night of Oct. 25, 2011. The Iraq War vet remembers leaving his tech job in the San Francisco Bay Area and taking a BART train to join an Occupy Oakland protest against economic and social inequality. He remembers standing near protesters who faced off with Oakland police officers bristling with riot gear. He remembers being carried away by other protesters. But not the moment when a bean bag round fired from an officers 12-gauge shotgun crashed into the left side of his head, fracturing his skull and inflicting a near-fatal brain injury that forced him to relearn how to talk. (Slack, Wagner, Hancock, McCoy, 7/24)

Kaiser Health News: Technology Divide Between Senior Haves And Have-Nots Roils Pandemic Response Family gatherings on Zoom and FaceTime. Online orders from grocery stores and pharmacies. Telehealth appointments with physicians. These have been lifesavers for many older adults staying at home during the coronavirus pandemic. But an unprecedented shift to virtual interactions has a downside: Large numbers of seniors are unable to participate. (Graham, 7/24)

Kaiser Health News and PolitiFact: With DACA Ruling, Did Supreme Court Grant Trump New Powers To Reshape Health Care? President Donald Trump came into office vowing to repeal and replace Obamacare. While he successfully neutralized the health care laws requirement that everyone carry insurance, the lawremains in effect. When Fox News host Chris Wallace noted that Trump has yet to put forward a replacement plan, Trump told him to stay tuned. Were signing a health care plan within two weeks, a full and complete health care plan that the Supreme Court decision on DACA gave me the right to do, Trump saidJuly 19 on Fox News Sunday. (Greenberg, 7/24)

Kaiser Health News: Lost On The Frontline A lab assistant who spoke out about employee safety. A disease intervention specialist who hoped to follow her mother into nursing. A father of three who juggled jobs at three nursing homes. These are some of the people just added to Lost on the Frontline, a special series from The Guardian and KHN that profiles health care workers who died of COVID-19. (7/24)

The Wall Street Journal: U.S. Coronavirus Deaths Surpass 144,000 The U.S. death toll from the coronavirus pandemic rose above 144,000 as several states reported record single-day fatalities. The U.S. reported more than 68,000 new cases Thursday, slightly lower than the previous days tally. The nation accounts for more than a quarter of the more than 15.5 million coronavirus cases world-wide, according to data compiled by Johns Hopkins University. Higher case counts in the U.S. are partly attributable to expanded testing across the country, while a patchwork of rules and regulations has contributed to a resurgence of new cases. (Hall, 7/24)

CIDRAP: Just A Few Nations Driving Much Of World's COVID-19 Surge The global surge in COVID-19 cases is mainly driven by intense transmission in a relatively few countries, the head of the World Health Organization (WHO) said today, with South Africa now among the five hardest-hit countries. The global total today is at 15,348,877 cases, and 626,190 people have died from their illnesses, according to the Johns Hopkins online dashboard. (Schnirring, 7/23)

The New York Times: Its Emotional Whiplash: California Is Once Again At The Center Of The Virus Crisis When everything shut down in March as the coronavirus took off in California, Canters Deli, a mainstay in the Fairfax District of Los Angeles, laid off dozens of employees. A few months later, it called them back to work. By then, the state appeared to have emerged from the initial virus crisis in much better shape than other parts of the country. But now Californias caseload is exploding, with rising deaths and hospitalizations. As quickly as things had opened up, they have shut down again. (Arango and Mervosh, 7/23)

The Hill: California, Florida Report Record Numbers Of Daily Deaths California and Florida reported record numbers of daily coronavirus fatalities Thursday, as the total number of infections in the U.S. surpassed 4 million. California's 157 deaths on Wednesday continued aweek of coronavirus records in the state that had once been considered a COVID success story. Gov. Gavin Newsom (D) on Wednesday said 12,807 new coronavirus infections had been reported statewide in 24 hours, a record high.(Weixel, 7/23)

Politico: Spiking Or Plateauing? Covid-19 Case Counts Spur Debate A monthlong resurgence in Covid-19 cases appears to be hitting a peak, but a new assessment of the coronavirus trajectory is fueling conflicting interpretations about whether the worst is over. Slowing caseloads in Florida and Arizona have fanned a narrative that the worst of the disease spread is cresting in some of the nations worst hot spots repeating a pattern seen in early June. But public health experts on Thursday issued new warnings that the virus is still spiraling out of control, only in the form of a rolling series of outbreaks in almost half the states, with more troubling signs in many others. (Doherty, 7/23)

The Hill: Trump Likely To Sign Executive Orders On Drug Pricing Friday President Trump is likely to sign executive orders on Friday aimed at lowering drug prices, elevating a key issue for voters in an election year.While the plans could shift at the last minute, some GOP lawmakers have been invited to a presidential event on drug pricing Friday at 3 p.m. at the White House in the South Court Auditorium to make the announcement, according to an invitation obtained by The Hill. (Sullivan, 7/23)

The New York Times: Trump Moves To Roll Back Obama Program Addressing Housing Discrimination The rule, introduced in 2015, requires cities and towns to identify patterns of discrimination, implement corrective plans and report results. The administrations decision to complete a process of rescinding it culminates a yearslong campaign to gut the rule by conservative critics and members of the administration who claimed it overburdened communities with complicated regulations. (Fuchs, 7/23)

Los Angeles Times: Trump Repeals Housing Rule, Amplifying Appeals To Racial Bias With President Trump facing sagging support in the suburbs, his administration on Thursday targeted an Obama-era affordable housing regulation, the latest in a series of appeals to white voters fears of crime and declining property values. The U.S. Department of Housing and Urban Development announced that it would scrap a regulation known as Affirmatively Furthering Fair Housing, which was implemented by President Obama in an attempt to promote more integrated communities. Under the rule, cities receiving some federal housing aid had to develop plans to address patterns of segregation or risk losing money. (Megerian, Dillon and Stokols, 7/23)

Politico: Trump Administration Renews Public Health Emergency After Urging From States The Trump administration has renewed the public health emergency for the coronavirus, ensuring that critical resources to fight the pandemic can continue while much of the country battles rising caseloads. The news will come as relief to health care groups who worried that President Donald Trump would let the emergency declaration lapse when it was set to expire July 25, despite previous assurances from top administration officials it would be renewed. (Roubein, 7/23)

Politico: Trump Warns Of 'Greater Mortality' If Schools Don't Reopen President Donald Trump is still demanding schools reopen, even after nixing his Republican National Convention keynote events in Florida next month. The president argued Thursday that "a permanent shutdown was never the strategy, which would ultimately lead to greater mortality and irreversible harm." The prosperity of the U.S. economy hinges on children returning to school in person this fall, he contended, noting that the Council of Economic Advisers has estimated more than 5 million parents won't be able to go back to work if their kids don't return to campus. (Quilantan and Miranda Ollstein, 7/23)

AP: In Shift, Trump Says Some Schools May Need To Delay Opening Softening his earlier stance, President Donald Trump on Thursday acknowledged that some schools may need to delay their reopening this fall as the coronavirus continues to surge. It marks a shift from Trumps previous demand for a full reopening of the nations schools. Speaking at a White House news conference, Trump said districts in some virus hot spots may need to delay reopening for a few weeks. He said the decision will fall to governors. (Binkley, 7/23)

The Hill: Trump Cancels GOP Convention Plans In Jacksonville President Trump said Thursday that he would cancel the GOP convention events in Jacksonville, Fla., in August, saying it wasnt the right time due to the coronavirus. I told my team it's time to cancel the Jacksonville component of the GOP convention, Trump told reporters at a news conference at the White House. Ill still do a convention speech in a different form, but we wont do a big crowded conventionper se. Its just not the right time for that." (Chalfant, 7/23)

The New York Times: Trump Abruptly Cancels Republican Convention In Jacksonville: Its Not The Right Time The surprise announcement threw one of the tent-pole moments of Mr. Trumps re-election effort into limbo, with the president describing in vague terms how the Republicans would hold his renomination in North Carolina and do other things with tele-rallies and online. It was an ill-defined sketch of an August week that Mr. Trump once envisioned drawing huge crowds and energizing his struggling bid for a second term. (Haberman, Mazzei and Karni, 7/23)

Politico: How Trump Went From A Massive Convention Bash To No Party At All On Wednesday evening, President Donald Trump convened his top political advisers, including campaign manager Bill Stepien and Republican National Committee Chairwoman Ronna McDaniel, for a conference call to consider a move that would have been unthinkable just a few weeks ago: Cancel his partys upcoming convention in Jacksonville, Fla. By Thursday afternoon, with coronavirus raging in the state, the president who all year envisioned a boisterous send-off to the final months of his reelection campaign, had made up his mind: It was a no-go. (Isenstadt, Dixon and Fineout, 7/23)

The Hill: Trump Administration Recommends Against Universities Requiring COVID-19 Tests Before Students Return The Trump administration said Thursday it is not recommending universities require students be tested for COVID-19 before they head back to campus this fall. In general, testing people before going back to the university is not a strategy that we recommend, nor does the CDC recommend, because you're only negative for that one moment, Adm. Brett Giroir, assistant secretary at the Department of Health and Human Services who is in charge of COVID-19 testing strategy, told reporters. (Hellmann, 7/23)

The Hill: Fauci: With Vaccine, 'We Could Start Talking About Real Normality Again' In 2021 The completion of a coronavirus vaccine could allow the U.S. to return to real normality in 2021, Anthony Fauci, the nations top infectious diseases expert, said Thursday. "The timetable of getting into 2021, well into the year, then I can think with a successful vaccine if we could vaccinate the overwhelming majority of the population we could start talking about real normality again," Fauci said Thursday on CNN contributor David Axelrods podcast The Axe Files. "But it is going to be a gradual process." (Budryk, 7/23)

The Hill: Fauci Says That He And His Family Have Experienced 'Serious Threats' During Pandemic Anthony Fauci, the nations top infectious diseases expert, said Thursday that he has received serious threats to himself and his family since he became one of the public faces of the federal response to the coronavirus pandemic. The doctor said that the anger has appeared on a different level than when he began his work during the HIV/AIDS crisis. (Budryk, 7/23)

The Hill: Birx Warns Of Disturbing Rise Of Coronavirus Cases In 12 Cities White House coronavirus task force coordinator Deborah Birx saidin a private meeting with local and state health officials that the task force is tracking increases in the virus in 12 U.S. cities. "There are cities that are lagging behind and we have new increases in Miami, New Orleans, Las Vegas, San Jose, St. Louis, Indianapolis, Minneapolis, Cleveland, Nashville, Pittsburgh, Columbus and Baltimore, so we're tracking this very closely, Birx said in the audio, first obtainedby the nonprofit Center for Public Integrity. We're working with the state officials to make sure we're responding together, but when you first see that increased test positivity, that is when to start the mitigation efforts." (Budryk, 7/23)

The Hill: Obama: US Not Dealing With Coronavirus As 'Smartly' As Other Countries Former President Obama saidin remarks released Thursdaythat the U.S. is not dealing with the coronavirus pandemic as smartly as other countries with similar resources. The former president made the remarks during a conversation with presumptive Democratic presidential nominee Joe Biden, saying he was confident that if his former vice president is elected in November he will respond to the crisis effectively. (Klar, 7/23)

NBC News: Despite Judge's Order, Migrant Children Remain Detained Amid COVID Outbreak Nearly a month after a federal judge ruled the Trump administration must release migrant children "with all deliberate speed" from Immigration and Customs Enforcement detention centers because of COVID-19, 346 parents and children are detained in facilities with outbreaks and court filings show releases remain rare. When U.S. District Judge Dolly Gee ordered the release of children detained with their parents in late June, she was explicit in her reasoning. The ICE facilities, she said, were "on fire and there is no more time for half measures." (Soboroff, 7/23)

Politico: Marine Assigned To Trump's Helicopter Squadron Tests Positive For Covid-19 A Marine assigned to the military helicopter squadron responsible for transporting the president has tested positive for Covid-19, a Marine Corps spokesperson told POLITICO. The Marine, assigned to Marine Helicopter Squadron 1, was tested on Tuesday and received the positive result on Thursday, said spokesperson Capt. Joseph Butterfield, adding that the squadron administers 80 to 100 tests per week. (Seligman, Lippman and Caputo, 7/23)

The New York Times: Republican Stimulus Talks Stall Over Differences On Unemployment Republicans stumbled on Thursday in their efforts to find agreement on a broad new proposal to lift the struggling economy, with Senate leaders and the Trump administration at odds over multiple provisions, including how to extend unemployment benefits and White House requests for spending unrelated to the pandemic. Even after President Trump folded on one of his key demands, for a payroll tax cut, negotiations bogged down over details of the package, including how to reduce the amount of money that Americans are currently receiving as unemployment benefits. (Cochrane, Tankersley and Rappeport, 7/23)

The Hill: Senate GOP Punts Coronavirus Package To Next Week GOP senators expected to introduce the package of bills on Thursday after days of closed-door haggling among themselves and the White House and publicly struggling to get on the same page. But Senate Majority Leader Mitch McConnell (R-Ky.) said key senators will instead unveil it Monday, pointing at the White House as the reason behind the delay. (Carney, 7/23)

Politico: As Unemployment Grows, White House And Senate GOP Stumble On Virus Talks Senate Republicans were forced to delay the rollout of a $1 trillion coronavirus relief package after differences between the White House and GOP leadership derailed the timing for unveiling the measure an embarrassing setback that could have serious consequences for millions of unemployed Americans. The main area of dispute was over extension of federal unemployment assistance for workers that have lost their jobs as the United States economy shut down during in response to the coronavirus pandemic. These $600-per-week payments begin to expire this week. Just on Thursday, the federal government announced that 1.4 million new unemployment claims had been filed in the past week. (Bresnahan and Levine, 7/23)

AP: Jobless Claims Rise As Cutoff Of Extra $600 Benefit Nears The nation got another dose of bad economic news Thursday as the number of laid-off workers seeking jobless benefits rose for the first time since late March, intensifying concerns the resurgent coronavirus is stalling or even reversing the economic recovery. And an extra $600 in weekly unemployment benefits, provided by the federal government on top of whatever assistance states provide, is set to expire July 31, though this is the last week recipients will get the extra funds. It is the last major source of economic help from the $2 trillion relief package that Congress approved in March. A small business lending program and one-time $1,200 payment have largely run their course. (Rugaber, 7/24)

The New York Times: Heres How Congress Might Replace The Extra $600 Weekly Jobless Benefit An additional $600 per week that has provided a vital financial cushion for unemployed Americans is set to expire next week. On Thursday, top Republicans said they had reached agreement on a proposal to replace a benefit that has helped millions of laid-off workers and been a boon to consumer spending amid a deep recession. Their plan would continue to offer larger-than-normal payments to workers filing for unemployment benefits. But it would significantly reduce the amount of money flowing each week to those without a job, at a time when 30 million people remain unemployed and the recovery from a pandemic recession is stuck in the mud. (Tankersley and Casselman, 7/23)

The Hill: Democrats Hit Interior Secretary For Reportedly Refusing To Wear Mask In Meeting With Tribes Three Democratic senators are criticizingInterior Secretary David Bernhardtover reports that he refused to wear a mask in a meeting with tribes in Oregon earlier this month. On your July 9 visit with the Klamath Tribes of Oregon, the tribe expressed concerns that you and a member of the U.S. House of Representatives from the State of California refused to wear a mask wrote Democratic Sens. Elizabeth Warren (Mass.), Ron Wyden (Ore.) and Jeff Merkley (Ore.). (Frazin, 7/23)

The Wall Street Journal: China Says It Will Have Covid-19 Vaccine Ready This Year One of the first Chinese projects to start testing its Covid-19 vaccine candidates overseas said it would have a vaccine ready for the public before the end of the year. Liu Jingzhen, chairman of state-owned China National Pharmaceutical Group, also known as Sinopharm, said on state broadcaster CCTV on Tuesday that clinical trials that began in Abu Dhabi last week should be completed in roughly three months, paving the way for a vaccine to go to the market this year. (Deng, 7/23)

The New York Times: Who Gets The Covid-19 Vaccine First? Heres One Idea When a coronavirus vaccine becomes available, who should get it first? A preliminary plan devised by the Centers for Disease Control and Prevention this spring gives priority to health care workers, then to people with underlying medical conditions and older people. The C.D.C. has not yet decided whether the next in line should be Blacks and Latinos, groups disproportionately affected by the coronavirus .But lets suppose that health care workers and people with underlying medical conditions use up the first doses of the available vaccine. Should some be held in reserve for Black and Latino people? What about bus drivers and train conductors? Perhaps teachers or schoolchildren should get it so they can return to classrooms with peace of mind. (Kolata, 7/23)

Stat: Ruling Threatens To Upend Patents On Modernas Covid-19 Vaccine Moderna, racing to develop a vaccine for Covid-19, lost a key patent decision Thursday, one that could delay the companys progress or force it to hand over a cut of profits. The U.S. Patent and Trademark Office denied Modernas claim that a patent held by a rival company was invalid. The patent, which covers technology used to deliver messenger RNA treatments, is held by the Canadian firm Arbutus. (Garde, 7/23)

Stat: Covid-19 Streamlined FDA Rules, And Pharma's Pushing To Keep It That Way The pharmaceutical industry made it clear to the Food and Drug Administration that it wants the regulatory flexibilities the agency has embraced during the Covid-19 pandemic to be made permanent and its ready to push to make sure it happens.There is a pressing need for FDA and industry to identify actions taken during the Covid-19 pandemic and evaluate their effectiveness and applicability to innovative drug development beyond the public health emergency, said Lucy Vereshchagina, vice president of science and regulatory affairs at PhRMA. (Florko, 7/23)

The New York Times: Coronavirus Testing Labs Again Lack Key Supplies Labs across the country are facing backlogs in coronavirus testing thanks in part to a shortage of tiny pieces of tapered plastic. Researchers need these little disposables, called pipette tips, to quickly and precisely move liquid between vials as they process the tests. As the number of known coronavirus cases in the United States passes 4 million, these new shortages of pipette tips and other lab supplies are once again stymieing efforts to track and curb the spread of disease. (Wu, 7/23)

The New York Times: Testing Bottlenecks Threaten N.Y.C.s Ability To Contain Virus Nearly four months after the pandemics peak, New York City is facing such serious delays in returning coronavirus test results that public health experts are warning that the problems could hinder efforts to reopen the local economy and schools. Despite repeated pledges from Gov. Andrew M. Cuomo and Mayor Bill de Blasio that testing would be both widely accessible and effective, thousands of New Yorkers have had to wait a week or more for results, and at some clinics the median wait time is nine days. One prominent local official has even proposed the drastic step of limiting testing. (Goldstein and McKinley, 7/23)

The Wall Street Journal: Baseballs Opening Day Rocked By Covid-19 Tests For Nationals Star Juan Soto After months of detailed drafting, Major League Baseballs return-to-play plan couldnt make it to the seasons first pitch before facing a problem that demonstrates the enormous challenge of playing amid the coronavirus pandemic. About five hours before the Washington Nationals were set to play the first game of the shortened 2020 campaign against the New York Yankees, the team announced that star outfielder Juan Soto had tested positive for Covid-19. Upon finding out Thursday, the 21-year-old Soto took multiple rapid-response coronavirus tests that came back negative, a person familiar with the matter said. Nonetheless, Soto must sit out until he produces two lab-confirmed negative tests, spaced 24 hours apart. The entire episode provided insight into the fragility of baseballs carefully crafted protocolsand how difficult it will be to avoid an outbreak of infection over the next three months. (Diamond and Radnofsky, 7/23)

CIDRAP: Chronic Conditions Put Nearly Half Of US Adults At Risk For Severe COVID-19 About 47% of US adults have an underlying condition strongly tied to severe COVID-19 illness, researchers at the Centers for Disease Control and Prevention (CDC) have found. The model-based study, published today in the CDC's Morbidity and Mortality Weekly Report, used self-reported data from the 2018 Behavioral Risk Factor Surveillance System and the US Census. (Van Beusekom, 7/23)

CIDRAP: Live COVID-19 Virus Isolated From Human Nose-Throat, Saliva Specimens A small study published yesterday in Clinical Microbiology and Infection found live SARS-CoV-2, the virus that causes COVID-19, in one nose-throat swab and two saliva specimens of five infected hospital patients in Korea 11 to 15 days after symptom onset. Researchers collected nose-throat swabs, saliva, urine, and stool samples from the patients hospitalized from Feb 25 to Mar 5 on days 8, 11, 13, 15, and 30 after study enrollment. They performed quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to detect SARS-CoV-2 RNA and cell culture to detect viable virus. No live virusonly viral RNAwas isolated on cell culture from five urine, two saliva, four nose-throat, and three fecal specimens. (7/23)

Stat: Scientists Are Developing Synthetic Biosensors To Monitor Lung Disease Imagine inhaling a sensor that could monitor lung disease patients response to therapy, emitting a signal when they breathe out. Like a breathalyzer that recognizes alcohol, such a device could sniff out compounds released only by specific illnesses to gauge how well treatment is working. Biomedical engineers at the Massachusetts Institute of Technology have developed a synthetic biosensor using specialized nanoparticles to detect and then report the presence of molecules indicating bacterial pneumonia or the genetic disease alpha-1 antitrypsin deficiency. (Cooney, 7/24)

AP: FDA Tells Doctors To Discuss Overdose Antidote With Patients Prescribing instructions for all opioids, such as Percocet and OxyContin, will recommend doctors discuss how to get the overdose-reversal drug, which can be obtained from pharmacists without a prescription. For patients with a higher risk of overdose, such as those with a history of opioid addiction, doctors should consider prescribing naloxone alongside the opioid. The same recommendations will appear on drugs used to control opioid addiction, such as methadone. (Perrone, 7/23)

Stat: FDA Says Opioid Labels Must Include Information About Naloxone The Food and Drug Administration announced Thursday that it would require drug manufacturers to include information about naloxone, the overdose-reversal medication, on the labels of opioid painkillers. The move comes just weeks after the federal government released new data showing that U.S. drug overdose deaths reached an all-time high in 2019, surpassing the previous peak recorded two years earlier. (Facher, 7/23)

The New York Times: How Play Energizes Your Kids Brain To the untrained eye, play can seem aimless, repetitive, wild or foolish. But play can offer a window into the developing mind. Piaget viewed certain kinds of play as milestones, signs that a child had reached a new stage of development. Studies conducted over the past few decades suggest play serves a more crucial role. Play can help kids learn, plan and even persevere in the face of adversity. (Willyard, 7/21)

The New York Times: Should 5-Year-Olds Start School This Year? Alka Tripathy-Langs 5-year-old son is supposed to start kindergarten this fall, but her district in suburban Phoenix has already delayed its start and announced that classes, when they do start, will be online for at least the first couple of weeks. What those lessons will look like is unclear, as are details about how much parental involvement will be required, and how or when the school is going to implement the dual immersion Mandarin program her son is supposed to begin. Tripathy-Langs current plan is to start him in an online-only option, but if its not working, shell pull him out to be home with her 3-year-old, who she and her husband have already decided not to send to preschool this year. (Sohn, 7/23)

The Washington Post: Librarians Alarmed About Coronavirus Safety At D.C.s Reopened Public Libraries When the Districts public libraries began gradually reopening in late May, many residents rushed to check out books for the first time in six weeks. By mid-July, the library was opening its doors for six hours a day, five days a week, for patrons who could come inside to borrow items and spend time using public computers at 14 locations. But librarians say the reopening has been poorly handled, exposing both staff members and the public to potential coronavirus risks. They also say library managers have kept staff in the dark about colleagues who come down with the virus and have struggled with cleaning protocols and mask requirements. (Zauzmer, 7/23)

The Wall Street Journal: Face Masks And A Mohel: Parents Figure Out How To Host A Bris During Coronavirus When Ben Sass and Aliza Jaffe Sass learned in January that they had a baby boy on the way, preparations for a bris started immediately. Along with the rest of the logistical advance work of pregnancy, they now had to decide which family members would have the honors of escorting their new son into the ceremony, who would hold the child during the circumcision procedure, and what they would serve their guests at the reception afterward. They didnt plan for how they would facilitate a surgery on an infant in their Philadelphia apartment during a global pandemic. (Rubin, 7/23)

CIDRAP: Nearly 60% Of US Parents Say They Won't Vaccinate Their Kids Against HPV Nearly 60% of the parents of about 4.3 million US children don't intend to have them vaccinated against the highly infectious and sexually transmitted human papillomavirus (HPV), according to survey results published earlier this week in The Lancet Public Health. Researchers at the University of Texas at Houston analyzed the data of parents of 82,297 children 13 to 17 years old from the 2017-18 National Immunization Study. They found even higher vaccine hesitancy rates (higher than 65%) in Idaho, Kansas, Michigan, Montana, Nebraska, North Dakota, Oklahoma, and Utah. (7/23)

Stat: New Research Finds A Wide Gulf In Engagement With Mental Health Apps A first-of-its-kind analysis, conducted in collaboration with researchers at Microsoft, paints a detailed picture of how people do or dont engage with virtual mental health tools, a step toward expanding the use of digital therapeutics. Lackluster engagement has long been a thorn in the health tech industrys side: As mental health tools proliferate, their uptake and long-term use remain relatively low. That problem has taken on new urgency as the pandemic shunts patients from in-person to online treatment. (Isselbacher, 7/24)

AP: Lawyer Defends Actions Of Vets Home Boss Amid Outbreak A Massachusetts home where nearly 80 aging veterans sicked with the coronavirus have died was denied emergency aid as leadership and staff frantically worked to protect the residents, an attorney for the ousted superintendent said Thursday. The attorney said state officials initially refused in March to send National Guard aid even as the home was dealing with dire staffing shortages. The lawyer for former Holyoke Soldiers Home Superintendent Bennett Walsh called him a good and honorable man who would never do anything intentional to harm the vets. (Durkin Richer, 7/23)

AP: Restraining Order Barring Nursing Home Closing Extended A southern Illinois judge on Thursday extended a temporary restraining order barring a nursing home from executing its closure plan until it has fulfilled all its obligations to residents. When Aperion Care Cairo announced its intention to close last week, families complained to Alexander County officials they felt rushed to select alternative placement for loved ones. (7/23)

The Washington Post: Meatpacking Workers File Lawsuit Against OSHA, Accusing Agency Of Failing To Keep Them Safe The Occupational Safety and Health Administration is failing to do its job properly, according to a lawsuit filed Thursday by three meatpacking workers, who say the agencys inaction has left them in danger. The lawsuit accuses OSHA of leaving the workers in imminent danger due to what they say are hazardous working conditions at the factory where they work, run by Maid-Rite Specialty Foods in Pennsylvania, in the midst of the coronavirus pandemic. (Rosenberg, 7/23)

Los Angeles Times: How To Say No To Parties During The COVID-19 Pandemic Of course you are allowed to say no. You are allowed to say that at all times, to all invitations, under all circumstances. But especially right now, in the middle of a pandemic. So its less about whether you can say it and more about how, experts say. Tone matters. Put a smile on your face when you make the call and keep it simple: Thank you for the invitation, Im so sorry but I cant make it. (Roy, 7/23)

Reuters: Georgia's Governor And Atlanta's Mayor Ordered To Mediate Coronavirus Mask Fight A Georgia judge on Thursday ordered the governor and Atlantas mayor to enter mediation over the governors lawsuit aimed at stopping the city from enforcing its requirement that people wear masks in public during the coronavirus pandemic. Fulton Superior Court Judge Jane Barwick ordered Governor Brian Kemp and Mayor Keisha Lance Bottoms to attend mediation with another judge and try to resolve the dispute before an emergency hearing scheduled in the case for Tuesday. (McKay, 7/23)

AP: Anchorage Mayor To Impose New Restrictions Amid Virus Cases The mayor of Anchorage is limiting gathering sizes and the number of people allowed in bars, restaurants and entertainment venues in response to rising coronavirus cases. The order, by Mayor Ethan Berkowitz, takes effect Friday and says that due to a resurgence in cases there is a need for increased restrictions on public interactions to preserve health and save lives in our community. (Bohrer, 7/23)

AP: North Dakota Governor Blasts Party's Anti-LGBTQ Resolution North Dakotas Republican governor on Thursday blasted an anti-LGBTQ resolution that was passed by hundreds of his partys delegates, calling it insulting and divisive. The resolution one of dozens of party policy statements in a passed by this spring by mail-in ballot states that many LGBT practices are unhealthy and dangerous, sometimes endangering or shortening life and sometimes infecting society at large. Gov. Doug Burgum issued a statement Thursday denouncing the resolution. (MacPherson, 7/23)

The Hill: Two Florida Mayors Urge Residents To Wear Masks At Home Two Florida mayorswho governMiami and Miami-Dade County encouraged their residents on Thursday to wear masks inside to lower the transmission rate of COVID-19 between family members. Miami Mayor Francis Suarez (R) explained that while the city's number of daily new cases is down, the virus is still being spread easily through households, as multigenerational households are commonplace in Miami. (Johnson, 7/23)

Stat: San Francisco Official Pushes City To Condemn Hospitals Zuckerberg Name A San Francisco city official is introducing a resolution to condemn the citys public hospital for naming itself after Mark Zuckerberg the latest escalation of a five-year quest, led mostly by nurses and other health care workers, to disassociate the institution from the controversial Facebook founder. The resolution, introduced late Thursday by San Francisco supervisor Gordan Mar, wouldnt strip the hospital of the Zuckerberg name, bestowed on the hospital after he and his wife, pediatrician Priscilla Chan, donated $75 million to the institution in 2015. (Ortolano, 7/24)

AP: 6 Downstate Illinois Counties Sue Over COVID-19 Restrictions Residents in six central and southern Illinois counties, including the state capitals home, filed lawsuits Thursday against Gov. J.B. Pritzkers restrictions on social interaction prompted by the coronavirus pandemic. The actions taken in Bond, Clay, Clinton, Edgar, Richland and Sangamon counties seek court orders declaring there is no public health emergency as defined by Pritzkers Public Health Department. Springfield, the state capital, is in Sangamon County. (7/24)

AP: Inslee Shuts Indoor Service At Bars, Restricts Indoor Dining Washington Gov. Jay Inslee said Thursday he is tightening restrictions throughout the state in restaurants and bars, for weddings and funerals, and at gyms in a further effort to stem a surge in COVID-19 cases. I care about businesses opening and people getting back to work, but public health and economic activity go hand in hand, Inslee said. If we let this virus get even more out of control, it will have devastating effects on our health and on our economy. (Baumann, 7/24)

Link:
First Edition: July 24, 2020 - Kaiser Health News